Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group

Kanika Kamal(Brigham and Women's Hospital), Arash Mostaghimi(Brigham and Women's Hospital), Anna L. Cogen(University of California San Diego), Alireza Firooz(Tehran University of Medical Sciences), João Renato Vianna Gontijo(Universidade Federal de Minas Gerais), Joachim Dissemond(Essen University Hospital), Lars E. French(University of Miami), Eric Xia(Boston University), Robert Bissonnette(Innovaderm (Canada)), Alex G. Ortega‐Loayza(Oregon Health & Science University), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Cathryn Sibbald(University of Toronto), Jeffrey P. Callen(University of Louisville), Sara J. Li(Tufts University), Toshiyuki Yamamoto(Fukushima Medical University), Anthony P. Fernandez(Cleveland Clinic), Afsáneh Alavi(Mayo Clinic in Arizona), Stanislav N. Tolkachjov(Baylor University Medical Center), Benjamin H. Kaffenberger(The Ohio State University Wexner Medical Center), Sheila Shaigany(Donald & Barbara Zucker School of Medicine at Hofstra/Northwell), Lisa J. Gould(Kent Hospital), Kave Shams(University of Leeds), William W. Huang(University of North Carolina Health Care), Angelo Valerio Marzano(University of Milan)

Journal of Investigative Dermatology

December 16, 2023

Cited by 2

|Science|1996|1.3k

|Journal of the American Academy of Dermatology|2006|654

|Journal of the National Comprehensive Cancer Network|2020|484

|Journal of Investigative Dermatology|1999|437

|Journal of the European Academy of Dermatology and Venereology|2022|419

Related Papers